You need cookies enabled

HEFCE closed at the end of March 2018. The information on this website is historical and is no longer maintained.

Many of HEFCE's functions will be continued by the Office for Students, the new regulator of higher education in England, and Research England, the new council within UK Research and Innovation.

The HEFCE domain - - will continue to function until September 2018. At this point we will close the site entirely and all its information will only be available from the National Web Archive.


You need cookies enabled

The institute will bring together multi-disciplinary teams of scientists, academic clinicians, clinical trial specialists and nurses. These teams will aim to:

  • develop therapies that enhance immunity for the treatment of cancer and chronic infection
  • identify ways to treat autoimmune conditions and prevent immune attack of conventional and bioengineered transplants.

To consolidate the strength of its research, the institute will partner with another biomedical research centre - the Francis Crick Institute. Working with other university partners will also provide access to a patient population of six million.

State-of-the-art research labs, equipment and clinical-trial facilities will allow researchers to rapidly adapt their research methods to produce therapeutics for trial with patients.

The institute will work with industry and the technology and innovation centre, Cell Therapy Catapult. This will help to increase the scale of the institute’s work and develop new forms of tissue, cell and gene therapy for the benefit of patients.

Phase I of the Institute, comprising 18002m of refurbished space, opened in June 2013. A new institute building will be completed in 2017, and will provide space for 20-25 research groups, each with 8-10 researchers. 

Main contact

Name Professor Hans Stauss
Title Director of the Institute of Immunity & Transplantation
Tel 0207 794 0500  x33321

Page last updated 26 February 2015